PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+19.19%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$783M
AUM Growth
+$783M
(+6.7%)
Cap. Flow
-$26.8M
Cap. Flow
% of AUM
-3.42%
Top 10 Holdings %
Top 10 Hldgs %
34.67%
Holding
106
New
16
Increased
38
Reduced
39
Closed
12
Top Buys
| 1 |
Teleflex
TFX
|
$23.8M |
| 2 |
Keros Therapeutics
KROS
|
$13M |
| 3 |
Stryker
SYK
|
$10.1M |
| 4 |
Viridian Therapeutics
VRDN
|
$9.67M |
| 5 |
Arcus Biosciences
RCUS
|
$9.33M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$17M |
| 2 |
Elevance Health
ELV
|
$15M |
| 3 |
Humana
HUM
|
$11.2M |
| 4 |
Tenet Healthcare
THC
|
$9.17M |
| 5 |
Boston Scientific
BSX
|
$8.75M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Boston Scientific
BSX
$156B
| $37.5M | 4.78% | 447,196 -104,396 | -19% | -$8.75M |
|
2
Insulet
PODD
$23.9B
| $37.2M | 4.74% | 159,689 -19,616 | -11% | -$4.57M |
|
3
Eli Lilly
LLY
$657B
| $35.8M | 4.57% | 40,384 +8,730 | +28% | +$7.73M |
|
4
Cooper Companies
COO
$13.4B
| $32.3M | 4.12% | 292,593 -15,805 | -5% | -$1.74M |
|
|
5
Keros Therapeutics
KROS
$618M
| $24.5M | 3.13% | 421,782 +223,155 | +112% | +$13M |
|
|
6
Teleflex
TFX
$5.59B
| $23.8M | 3.04% | +96,144 | New | +$23.8M |
|
|
7
United Therapeutics
UTHR
$13.8B
| $22.9M | 2.93% | 64,031 -47,350 | -43% | -$17M |
|
8
MannKind Corp
MNKD
$1.41B
| $20.8M | 2.65% | 3,304,085 +894,486 | +37% | +$5.63M |
|
9
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $18.9M | 2.41% | 755,244 +108,102 | +17% | +$2.7M |
|
|
VRNA
10
Verona Pharma
VRNA
$9.16B
| $18M | 2.3% | 626,452 +31,063 | +5% | +$894K |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $17.7M | 2.26% | 241,575 +56,547 | +31% | +$4.14M |
|
12
Edgewise Therapeutics
EWTX
$1.51B
| $17.5M | 2.24% | 657,070 +82,553 | +14% | +$2.2M |
|
|
LBPH
13
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $16.4M | 2.09% | 491,272 -202,906 | -29% | -$6.76M |
|
|
14
Arcus Biosciences
RCUS
$1.13B
| $15.7M | 2% | 1,025,754 +610,219 | +147% | +$9.33M |
|
|
15
Tenet Healthcare
THC
$16.3B
| $15.6M | 1.99% | 93,753 -55,174 | -37% | -$9.17M |
|
16
Travere Therapeutics
TVTX
$1.56B
| $15.2M | 1.94% | 1,086,067 +116,175 | +12% | +$1.63M |
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $15M | 1.91% | 129,840 +14,670 | +13% | +$1.69M |
|
18
Vaxcyte
PCVX
$4B
| $14.9M | 1.9% | 130,249 -19,942 | -13% | -$2.28M |
|
19
Becton Dickinson
BDX
$55.3B
| $14.5M | 1.85% | 60,011 -8,156 | -12% | -$1.97M |
|
20
Abbott
ABT
$231B
| $14.1M | 1.8% | 123,601 +1,688 | +1% | +$192K |
|
21
Day One Biopharmaceuticals
DAWN
$769M
| $12.9M | 1.64% | 924,140 +15,318 | +2% | +$213K |
|
22
Agios Pharmaceuticals
AGIO
$2.19B
| $12.7M | 1.62% | 285,099 -161,317 | -36% | -$7.17M |
|
23
Gilead Sciences
GILD
$140B
| $10.8M | 1.38% | 129,025 +4,025 | +3% | +$337K |
|
24
Schrodinger
SDGR
$1.44B
| $10.4M | 1.32% | 559,105 -162,268 | -22% | -$3.01M |
|
|
25
Stryker
SYK
$150B
| $10.1M | 1.29% | +28,000 | New | +$10.1M |
|